Geron Corporation (GERN)
NASDAQ: GERN
· Real-Time Price · USD
1.35
-0.03 (-2.17%)
At close: Oct 03, 2025, 2:29 PM
-2.17% (1D)
| Bid | 1.35 |
| Market Cap | 861.32M |
| Revenue (ttm) | 164.45M |
| Net Income (ttm) | -88.01M |
| EPS (ttm) | -0.13 |
| PE Ratio (ttm) | -10.38 |
| Forward PE | -141 |
| Analyst | Buy |
| Dividends | n/a |
| Ask | 1.36 |
| Volume | 7,539,624 |
| Avg. Volume (20D) | 8,462,380 |
| Open | 1.40 |
| Previous Close | 1.38 |
| Day's Range | 1.34 - 1.48 |
| 52-Week Range | 1.09 - 4.50 |
| Beta | 0.63 |
| Ex-Dividend Date | n/a |
About GERN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol GERN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for GERN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock ForecastsGeron Corporation is scheduled to release its earnings on
Nov 6, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
+15.83%
Geron shares are trading higher after the company ...
Unlock content with
Pro Subscription
7 months ago
-32.07%
Geron Corporation shares are trading lower. The company reported Q4 financial results.
1 month ago · businesswire.com
Geron Appoints Harout Semerjian as President and Chief Executive OfficerFOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced the ...
2 months ago · businesswire.com
Geron Plans to Announce Second Quarter 2025 Financial Results on August 6, 2025FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today announced that it will release its second quarter financial results and busi...